If you want to own the companies that make medicines, medical devices and the health systems the developed world leans on more heavily every year, you do not need to pick individual pharma stocks. A single healthcare UCITS ETF gives you a diversified slice of the whole sector in one line of your portfolio, and Europeans have several good ones to choose from.
The honest short answer: for most people a broad healthcare fund such as an iShares or Xtrackers MSCI World Health Care ETF is the sensible way in. It spreads you across pharma, biotech, medical devices, insurers and life-science tools, so you are not betting on one drug or one trial. Narrower pharma-only or biotech-only funds exist, but they concentrate the risk, and I treat them as a smaller tilt rather than the main holding.
For the practical side, see the Vanguard vs iShares comparison.
For the practical side, see the Global X ETFs for European investors.
I have held a healthcare sleeve as a satellite in my own portfolio for years. It has been calmer than the tech names around it in bad markets, and that defensive quality is a big part of the appeal. But it is still a single sector, so it belongs at 5–15% of equities, not at the centre of your plan. Let me walk through the category, the numbers to check, and where it fits.
Why healthcare is the classic defensive-growth sector
Healthcare sits in an unusual spot. It is defensive, because people need treatment in a recession as much as in a boom, so revenues hold up when cyclical sectors wobble. But it is also a growth sector, because populations across Europe, the US and East Asia are ageing, and older people consume far more healthcare. That combination of steady demand and a structural tailwind is why the sector has quietly compounded for decades.
Selection criteria: the ETF selection methodology explains exactly how funds earn a place in this comparison.
The demographic case is the one I find most durable. The share of over-65s in the EU keeps climbing, medical technology keeps advancing, and middle-income countries keep spending more on health as they get richer. None of that depends on the economic cycle. It is one of the few genuinely long-run themes where the direction of travel is hard to argue with.
That said, defensive does not mean safe. The sector has real, specific risks that you are taking on when you buy it, and you should understand them before you commit money.
The risks you are actually taking
Three things can hurt a healthcare fund. First, patent cliffs: when a blockbuster drug loses exclusivity, generics flood in and revenue falls off a shelf, so a big pharma name can stall for years while it waits for the next launch. Second, regulation and drug pricing: US drug-pricing reform, European reference pricing and political pressure on costs all sit over the sector like a cloud, and a single policy headline can move the whole group. Third, US concentration: a global healthcare index is heavily weighted to American companies, so you are taking on a large dollar exposure and US policy risk whether you intended to or not.
A broad fund softens the first risk, because one patent cliff is diluted across dozens of holdings. It does nothing for the second and third. Keep that in mind when you size the position.
Broad healthcare versus narrow pharma and biotech
The category splits into three rough tiers, from widest to narrowest.
Broad healthcare is the widest. Funds tracking the MSCI World Health Care index, or the S&P 500 Health Care sector, hold the entire sector: large-cap pharma, biotech, medical devices, health insurers and the “picks and shovels” life-science tool makers. The main options European investors reach for are the iShares MSCI World Health Care Sector UCITS ETF, the Xtrackers MSCI World Health Care UCITS ETF, and the various SPDR sector funds. This is the diversified default, and it is what I mean when I say “a healthcare ETF”.
Pharma-tilted funds narrow the focus to drug makers, cutting out devices and insurers. You get more concentrated exposure to the medicines story but lose some of the balance that makes the broad funds resilient.
Biotech is a different animal entirely. Biotech funds are small-cap-heavy, driven by binary clinical-trial outcomes, and far more volatile — long, brutal drawdowns are normal. Biotech is a specialist satellite for risk-tolerant investors, not a substitute for broad healthcare. I have written the honest warning separately in the best biotech UCITS ETFs guide, and I would read it before you touch that corner. If you want the general lay of the land first, the healthcare, medical and biotech funds overview maps how the pieces connect.
What to compare before you buy
Sector ETFs look similar on the shelf, so a few data points separate them. Check the index first — MSCI World Health Care gives you global developed-market exposure, while an S&P 500 Health Care fund is US-only and more concentrated. Check the total expense ratio: broad healthcare funds sit in a roughly 0.15–0.45% range in 2026, with the big MSCI World trackers at the cheaper end and thematic tilts costing more. Treat every figure here as approximate and 2026-vintage — confirm the current TER, holdings and replication method on the provider’s own factsheet before you buy.
Also check accumulating versus distributing (accumulating reinvests dividends inside the fund, which suits long-term compounding and simpler tax admin in many countries), fund size and age (larger, older funds tend to be more liquid with tighter spreads), and domicile — an Irish-domiciled fund is usually the tax-efficient choice for most Europeans because of the US withholding-tax treaty. Our UCITS ETF comparison tool lets you line up TER, size and domicile side by side rather than eyeballing factsheets one at a time.
Learning ETFs the slow way?
The free 12-page Starter Kit gets you to a first, sensible portfolio faster: the 7-filter fund shortcut, the 3-question broker matrix, and the 7 costliest beginner mistakes.
| Feature | Broad healthcare (MSCI World Health Care) | Pharma / narrow tilt | Biotech |
|---|---|---|---|
| What it holds | Pharma, biotech, devices, insurers, life-science tools | Mainly drug makers | Small/mid-cap drug developers |
| Typical TER (approx, 2026) | ~0.15–0.45% | ~0.30–0.50% | ~0.35–0.65% |
| Volatility | Moderate, defensive | Moderate to high | High, deep drawdowns |
| Main risk | US weight, pricing policy | Patent cliffs | Trial outcomes, binary risk |
| Sensible portfolio weight | 5–15% of equities | Within that healthcare sleeve | ≤5–10%, risk-tolerant only |
How much healthcare should you hold?
This is where most people go wrong. A broad global index fund already contains around a tenth in healthcare, so buying a dedicated fund is a deliberate overweight, an active bet that the sector beats the market. That can be reasonable — I hold one — but treat it as a satellite, not a core. My rule of thumb is 5–15% of the equity side for a broad healthcare fund on top of a global core, and a good deal less for anything narrower.
If you already run a core-satellite structure, healthcare slots in beside your other thematic bets rather than replacing them. Think of it the same way you would a cybersecurity ETF or a robotics and automation ETF — a considered tilt with a clear thesis and a capped size, never the whole engine. The ETFs by category overview is a useful map if you are assembling several of these tilts.
My verdict — what I would do
If you want healthcare exposure and you want to keep it simple, buy one broad, Irish-domiciled, accumulating MSCI World Health Care UCITS ETF from a large provider and size it at around 5–15% of your equities. That gives you the defensive quality and the demographic tailwind without concentrating into a single drug, company or trial. You can confirm the current TER, holdings and share classes on the iShares official website or the equivalent Xtrackers page before you commit.
If you specifically want the higher-octane version and you can genuinely stomach a 40–50% drawdown without selling, add a small biotech satellite on top — but keep it tiny and read the risk warning first. For everyone else, broad healthcare is the answer, and pharma-only or biotech funds are optional extras rather than the starting point. Whatever you pick, buy it as a long-term holding and leave it alone; the sector rewards patience, not tinkering.
Frequently asked questions
Q: Is there a UCITS ETF for pharmaceutical companies?
A: Yes. European investors can buy broad healthcare UCITS ETFs such as the iShares or Xtrackers MSCI World Health Care funds, which hold large pharma companies alongside biotech, devices and insurers. There are also narrower pharma-tilted and biotech funds, though these concentrate the risk. Always confirm the exact fund, ticker and share class on the provider’s factsheet.
Q: What is the difference between a healthcare ETF and a biotech ETF?
A: A broad healthcare ETF spreads across pharma, biotech, medical devices, insurers and life-science tools, which makes it relatively defensive. A biotech ETF holds mostly small and mid-cap drug developers whose value swings on clinical-trial outcomes, so it is far more volatile with much deeper drawdowns. Healthcare is a core-friendly sector tilt; biotech is a specialist satellite.
Q: How much of my portfolio should be in a healthcare ETF?
A: A broad global index fund already holds roughly 10% in healthcare, so a dedicated fund is a deliberate overweight. A reasonable satellite size is around 5–15% of your equities on top of a global core, and less for narrower pharma or biotech funds. Treat it as a considered tilt, not a replacement for a diversified base.
Q: Are healthcare ETFs a good defensive investment?
A: Historically the sector has held up better than cyclical sectors in downturns because demand for medicines and care is steady regardless of the economy. It also has a structural tailwind from ageing populations. That said, it carries real risks — drug-pricing regulation, patent cliffs and heavy US concentration — so defensive does not mean risk-free.
Q: Should I choose an accumulating or distributing healthcare ETF?
A: For long-term investors in many European countries, an accumulating fund is simpler because it reinvests dividends inside the fund and can reduce annual tax admin. A distributing fund suits investors who want an income stream. The right answer depends on your own country’s tax rules, so check the local treatment or ask a tax adviser before deciding.
Q: Why are healthcare ETFs so heavily weighted to the US?
A: The largest pharmaceutical, biotech and medical-device companies in the world are disproportionately American, so a global healthcare index naturally reflects that. This gives you significant US dollar and US policy exposure, including sensitivity to American drug-pricing reform. It is not a flaw, but it is something to size and understand rather than ignore.
This guide is part of our hub on sector and thematic UCITS ETFs — browse the full cluster for related situations.
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →